	US 12,441,733 B2
	Substituted 2,4-dioxotetrahydropyrimidines as intermediates in the synthesis of bruton's tyrosine kinase inhibitors
Luca Arista, Riehen (CH); Christina Hebach, Muenchenstein (CH); Gregory John Hollingworth, Basel (CH); Philipp Holzer, Sissach (CH); Patricia Imbach-Weese, Bielefeld (DE); Julien Lorber, Colmar (FR); Rainer Machauer, Ehrenkirchen (DE); Niko Schmiedeberg, Riehen (CH); Anna Vulpetti, Basel (CH); and Thomas Zoller, Andolsheim (FR)
Assigned to NOVARTIS AG, Basel (CH)
Filed by Novartis AG, Basel (CH)
Filed on Feb. 15, 2023, as Appl. No. 18/169,361.
Application 18/169,361 is a continuation of application No. 16/981,059, granted, now 11,613,543, previously published as PCT/IB2019/052346, filed on Mar. 22, 2019.
Claims priority of application No. 18164076 (EP), filed on Mar. 26, 2018.
Prior Publication US 2024/0158399 A1, May 16, 2024
Int. Cl. C07D 239/22 (2006.01); C07D 487/04 (2006.01); C07D 519/00 (2006.01); A61K 45/06 (2006.01)

CPC C07D 487/04 (2013.01) [C07D 519/00 (2013.01); A61K 45/06 (2013.01)]

12 Claims

1. A compound of Formula (III), Formula (IIIa), Formula (XXIa), Formula (XXIII), or Formula (XLVI):

or a salt thereof,

wherein:

R⁶is H or F; and

R⁷is H, F, Cl, CH₃, OCH₃, or OCH₂CH₃.